biomodal Industry Symposium: Get it all in one workflow: Use duet cfDNA solutions to detect cancer earlier, monitor treatment response and understand tumour biology

duet cfDNA solutions are complete integrated genetic and epigenetic workflows and software that unlock the broadest spectrum of biomarkers from a single low input cfDNA sample. The workflows have been engineered for cfDNA applications to maximise the recovery of unique cfDNA molecules. Coupled with the full complement of biomarkers on each DNA fragment, duet cfDNA enables ultra-low LoD for the detection of ctDNA. The solution provides market-leading 6-base genetic and epigenetic accuracy, including the ability to distinguish 5mC from 5hmC, coupled with fragmentomic information. Providing a full complement of biomarkers on each DNA fragment enables ultra-low LoD for the detection of ctDNA. 6-base data has been shown to detect cancer earlier than other methylation sequencing approaches in multiple cohorts. Furthermore, analysis of cfDNA from a combination therapy clinical trial has demonstrated the power of the 6-base genome for better understanding the biological mechanism of prostate cancer treatment response.

Early detection of prostate cancer is challenged by low circulating tumor DNA (ctDNA) levels, limiting sensitivity. We evaluated whether combining methylation and fragmentomic features from cell-free DNA (cfDNA) improves detection. cfDNA from prostate cancer patients across disease stages and healthy controls was analyzed using a multiomics approach assessing 5mC, 5hmC, and fragmentomic features. Methylation signals reflected tumor biology but were less sensitive in localized disease, whereas fragmentomics provided more consistent discrimination across stages. Overall, fragmentomics offers a robust basis for early detection, and integrating both marker types is expected to further increase sensitivity and improve non-invasive prostate cancer diagnostics.